Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Carbon Monoxide for Pneumonia and Sepsis-Induced ARDS
NCT04870125Phase 1Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2023
- Primary completion
- Oct 2024
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Carbon monoxide in acute respiratory distress syndrome (ARDS) and sepsis (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Number of Pre-specified Administration-related Adverse Events at 7 days, Percentage Change Measured Relative to Target COHb Level and 1 more. Started Dec 2023; status: terminated.
02
Drugs
Carbon monoxide
03
Conditions
acute respiratory distress syndrome (ARDS)sepsis
Beyond the preview
Go deeper on NCT04870125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870125.